The changing landscape for COX-2 inhibitors: a summary of recent events.
Mamdani
Muhammad
M
Institute for Clinical Evaluative Sciences, University of Toronto Faculty of Pharmacy, Department of Health Policy, Management, and Evaluation, Ontario. muhammad.mamdani@ices.on.ca
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004335:Drug and Narcotic Control; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib